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Fig 1. Bullous erythema migrans in Lyme disease
(initial presentation): 12-cm annular, erythematous patch
with a centrally located 5-cm tender, indurated bulla with
surrounding vesicles.
Fig 2. Bullous Lyme disease (2 months after treatment
with doxycycline 100 mg by mouth, twice daily for
21 days): 5-cm patch of postinflammatory hyperpigmen-
tation and hypopigmentation.
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Bullous Lyme disease
To the Editor: A 57-year-old woman living in the
Upper Connecticut River Valley presented in July
2011 with an acute blistering rash on her left
thigh that she believed was caused by a spider bite.
The lesion rapidly progressed over 4 days from a
small tender red papule to a 12-cm annular,
erythematous patch with a centrally located 5-cm
tender, indurated bulla with surrounding vesicles
(Fig 1). She also reported mild fever, headache,
nausea, and arthralgia. She denied a history of a
recent tick bite, hiking, or recent travel, but she did
live in a wooded, rural area with numerous deer,
frequently used a riding lawn mower, and stated she
often saw ticks on her property.
The patient was seen by her primary care provider
and in the emergency department before presenting
to dermatology. Because of the bullous nature of the
eruption, the differential diagnosis included bite
reaction, cellulitis, herpes simplex, herpes zoster,
and Lyme disease. Initial workup included
complete blood cell count, basic metabolic panel,
blood cultures, bacterial and herpes simplex/
varicella-zoster virus cultures of the vesicular
fluid, herpes simplex/varicella-zoster virus rapid
stain, and Lyme IgG and IgM antibodies. All revealed
normal findings. Given our confidence this was
acute Lyme disease, we decided to treat the patient
with doxycycline (100 mg by mouth, twice daily for
21 days). The rash and systemic symptoms rapidly
resolved (Fig 2). Repeated Lyme antibody titers
drawn 8 weeks later were positive for IgM by
Western blot.
The first stage of Lyme disease usually features
erythema migrans at the site of inoculation,
accompanied by a flulike illness with nonspecific
symptoms of fatigue, myalgia, headache, and
fever. Of patients, 60% to 90% present with the
classic erythema migrans rash, described as anOpen access under CC BY-NC-ND license.erythematous macule that spreads centrifugally and
may develop central clearing.1 Atypical presenta-
tions have been reported, including hemorrhagic
and necrotic cutaneous changes.2,3 Vesicular or
bullous variants of erythema migrans are rare,
although 1 prospective study reported vesiculobul-
lous changes of the central portion of the lesion in 8%
of patients.4
The recognition of erythema migrans is
sufficiently distinctive to allow clinical diagnosis
and treatment of Lyme disease. In fact, the visual
inspection of the skin lesion is the preferred means
of diagnosis as serologic testing is too insensitive in
the acute phase of the disease (the first 2 weeks of
infection) to be helpful diagnostically,5 with IgM
antibodies usually becoming positive 2 to 6 weeks
after exposure.6 This requires the physician to
be aware of the classic appearance of erythema
migrans as well as its multiple atypical variants,
including bullous Lyme.
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E-mail: jeffreybtigermd@gmail.comFig 1. Mid-dermal elastolysis: asymptomatic parchment-
like appearance of the skin on the trunk.REFERENCES
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immune reconstitution inflammatory
syndrome in an HIV-infected patient
To the Editor: The immune reconstitution inflamma-
tory syndrome (IRIS) encompasses a group of
disorders with different clinical manifestations
occurring in HIV-infected patients after starting
highly active antiretroviral therapy (HAART),
resulting from the restored ability of the immune
system to mount an antigen-specific inflammatory
response. Previous studies have demonstrated that
10% to 25% of HIV-positive patients starting on
antiretroviral therapy experience IRIS, and in more
than half of them cutaneous involvement represents
the first manifestation of the disease.1
A 32-year-old Caucasian man with a 13-year
history of HIV infection (CD4 cell count 269 cells/
mm3, plasma HIV RNA load [VL] 16,315 copies/mL)
started HAART in December 2012. Two months later
his CD4 cell count increased to 465 cells/mm3, and
the viral load was undetectable. At the same time,
the patient reported a progressive, asymptomatic,
erythematous, parchment-like appearance of the
skin on his trunk (Fig 1). He denied prolonged
ultraviolet light exposure.A skin biopsy specimen showed a sparse
lymphohistiocytic infiltrate admixed with scattered,
multinucleated histiocytic giant cells arranged
between the collagen bundles in the mid dermis
(Fig 2, A). Focal elastophagocytosis was also noted.
Orcein staining highlighted a bandlike loss of elastic
fibers in the mid dermis (Fig 2, B). A diagnosis of
mid-dermal elastolysis was made. Four months
later the patient experienced gastrointestinal
symptoms associated with perianal fistulae. A
diagnosis of Crohn’s disease was confirmed
by radiologic, endoscopic, and histopathological
examination.
Mid-dermal elastolysis is a rare condition charac-
terized by localized, bandlike loss of elastic fibers in
the mid dermis.2 It presents clinically with variably
large areas of fine wrinkling, tiny perifollicular
papules, or both. The pathogenesis is unclear.
Several cases seem to be related to ultraviolet radi-
ation, whereas in others immunologic mechanisms
may be involved. The association with different
autoimmune disorders and the elevated antinuclear
antibody found in some patients with mid-dermal
elastolysis have supported the hypothesis of an
autoimmune origin.2
To our knowledge, mid-dermal elastolysis in the
course of HIV infection has been reported only
once.3 In contrast to our patient, the onset of skin
lesions was unrelated to treatment, and an
association with actinic damage was suggested as
